Insider Buying: Prenetics Global (NASDAQ:PRE) CEO Purchases $137,325.00 in Stock

Posted by Brian Himes on Aug 27th, 2026

Prenetics Global Limited (NASDAQ:PRE – Get Free Report) CEO Danny Sheng Wu Yeung bought 7,500 shares of Prenetics Global stock in a transaction on Thursday, August 20th. The stock was acquired at an average cost of $18.31 per share, with a total value of $137,325.00. Following the acquisition, the chief executive officer owned 95,235 shares of the company’s stock, valued at $1,743,752.85. This trade represents a 8.55% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Danny Sheng Wu Yeung also recently made the following trade(s):

On Monday, August 24th, Danny Sheng Wu Yeung bought 17,181 shares of Prenetics Global stock. The shares were bought at an average price of $21.23 per share, for a total transaction of $364,752.63.

Prenetics Global Stock Up 10.9%

NASDAQ:PRE opened at $25.78 on Thursday. The firm’s fifty day simple moving average is $19.24 and its 200-day simple moving average is $18.98. The stock has a market cap of $434.91 million, a PE ratio of -6.20 and a beta of 0.26. Prenetics Global Limited has a fifty-two week low of $7.27 and a fifty-two week high of $26.29.

Prenetics Global (NASDAQ:PRE – Get Free Report) last announced its quarterly earnings data on Wednesday, August 19th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.31. Prenetics Global had a negative net margin of 47.43% and a negative return on equity of 21.41%. The firm had revenue of $46.49 million during the quarter, compared to analysts’ expectations of $49.85 million. Equities analysts anticipate that Prenetics Global Limited will post -1.86 earnings per share for the current year.

Institutional Trading of Prenetics Global

Large investors have recently made changes to their positions in the stock. Wells Fargo & Company MN purchased a new position in Prenetics Global in the 4th quarter valued at about $47,000. State of Wyoming acquired a new position in shares of Prenetics Global in the first quarter valued at approximately $48,000. JPMorgan Chase & Co. purchased a new position in shares of Prenetics Global during the third quarter valued at approximately $65,000. Operose Advisors LLC purchased a new position in shares of Prenetics Global during the second quarter valued at approximately $129,000. Finally, Manatuck Hill Partners LLC acquired a new stake in Prenetics Global during the fourth quarter worth approximately $170,000. Institutional investors and hedge funds own 25.01% of the company’s stock.

Analyst Upgrades and Downgrades

PRE has been the topic of several research reports. Wall Street Zen raised Prenetics Global from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Prenetics Global in a research report on Friday, July 17th. Finally, Benchmark increased their price objective on shares of Prenetics Global from $30.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Prenetics Global currently has an average rating of “Moderate Buy” and an average target price of $34.25.

Read Our Latest Analysis on PRE

About Prenetics Global

(Get Free Report)

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.